Head-to-head evidence
IM21 CAR-T cells vs SENL103
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA · full Multiple Myeloma pipeline
IM21 CAR-T cells
Developed by Beijing Immunochina Medical Science & Technology Co., Ltd.
NCT03711864 · Phase 1 · status unknown
This is a small, unblinded, single-arm safety study with no comparison group, and no results have been posted yet.
SENL103
Developed by Hebei Senlang Biotechnology
NCT06067581 · Phase 1 · status unknown
This is a small, uncontrolled, open-label Phase 1 dose-escalation study with no comparator arm, designed to find a safe dose of SENL103 CAR-T therapy in heavily pretreated myeloma patients. Efficacy is only a secondary measure and no results have been posted, so there is no evidence yet of a clinical effect.
Next expected readout: February 2028 · NCT07421856 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: IM21 CAR-T cells's landscape · SENL103's landscape